Robert I. Scheinman

TL;DR: Feraheme is efficiently recognized via SR-AI/II but not via complement by different macrophage types, and the recognition by the common phagocytic receptor has implications for specificity of imaging of macrophages subtypes.

TL;DR: A regulatory approved PEGylated liposomal doxorubicin and empty liposomes of the same composition as LipoDox showed similar skin distribution as P EGylated egg PCliposomes, suggesting that this phenomenon is relevant to liposome of different lipid composition.

TL;DR: It is shown that FCN A and CL-11−/− mice are fully susceptible to collagen Ab–induced arthritis (CAIA), and FCN B and MASP-2 are substantially protected, with clinical disease activity decreased significantly and it is speculated that the residual disease seen in these studies is driven by the AP and/or the C2/C4 bypass pathway via the direct cleavage of C3 through an LP-dependent mechanism.

TL;DR: Results suggest that soluble domains of membrane-bound complement inhibitors are potential candidates for preventing nanomedicine-mediated complement activation in human subjects.

TL;DR: Data is interpreted as demonstrating that the activation caused by loss of Gimap5 is a cell intrinsic phenomenon caused, in part, by a MEK-dependent activation of IKK, which would suggest that Gimap 5 functions to promote both T cell survival and quiescence and that these pathways are biochemically linked.